A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease

• Status: Completed
• Trial end date: 2020-06-02
• Target enrollment: 0
• Participant gender: All

Summary

This trial aims to investigate the safety, tolerability and clinical activity of humanised antibody GSK1070806 delivered via intravenous infusion in the treatment of patients with moderate-to-severe Crohn's disease. 30-36 patients will be enrolled into the trial, with two thirds of the patients receiving active drug and one third receiving placebo. After 30 patients have been recruited into the study the sample size will be reassessed and up to an additional 6 patients could be recruited (i.e. up to 36 patients).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Birmingham
• Collaborators: GlaxoSmithKline; University Hospital Birmingham
• Treatments: Antibodies; Immunoglobulins

Criteria

Inclusion Criteria:

A patient will be eligible for inclusion in this study only if all of the following criteria apply:

1. Written informed consent prior to any of the screening procedures including discontinuation of prohibited medications. (see Section 7.11 for additional information)

2. Patients that have been diagnosed with moderate to severe Crohn's disease for at least 3 months prior to Screening Visit 1

3. Patients are required to have endoscopic evidence of active Crohn's disease at Baseline defined by endoscopic appearance: SES-CD excluding the narrowed component of ≥ 6 (or ≥4 for patients with isolated ileal disease).

4. AST and ALT ≤ 2xULN; alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)

5. Male or female participants aged ≥16 years (up to 80 years)

Male participants:

6. A male participant must agree to use contraception as detailed in Appendix 5 of this protocol for at least 180 days post-dose of study medication and refrain from donating sperm during this period.

Female participants:

7. If the patient is breastfeeding, she must agree to stop breastfeeding once randomised into the trial.*

8. A patient is eligible to participate if she is not pregnant.

9. A woman of childbearing potential (WOCBP) is eligible only if she meets at least one of the following conditions:

i. Females on HRT and whose menopausal status is in doubt will be required to use one of the non-hormonal highly effective contraception methods if they wish to continue their HRT during the trial. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before trial enrolment.

ii. Agrees to follow the contraceptive guidance in Appendix 5 for at least 180 days post-dose of trial medication. If a hormonal method of birth control is selected from the list in Appendix 5 then patients must have been using these methods at least 1 month prior to GSK1070806 administration, or be abstinent, or utilise a condom as a method of contraception until the selected hormonal method has been in place for the 28 day period.

10. A woman who is not of childbearing potential is eligible only if she meets at least one of the following conditions:

i. Premenopausal female with documented hysterectomy ii Premenopausal female with documented bilateral salpingectomy or oophorectomy iii. Postmenopausal female defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement

• A female patient who is breastfeeding may be screened. If randomised into the trial, this patient must agree to stop breastfeeding. Patients who are screened but ineligible can continue breastfeeding.

therapy (HRT). However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.

Exclusion Criteria:

A participant will not be eligible for inclusion in this trial if any of the following criteria apply:

1. Diagnosis of ulcerative or indeterminate colitis

Crohn's Disease complications:

2. Evidence of an infected abscess by MRI or other examinations

3. Bowel surgery other than appendectomy within 12 weeks prior to screen and/or has planned surgery or deemed likely to need surgery for CD during the trial period

4. Participants with ileostomies, colostomies or rectal pouches

5. Participants with a bowel stricture that is fixed

6. Participants with evidence of short bowel syndrome

7. Participants requiring enteral or parenteral feeding

8. Deep penetrating ulcers at endoscopy thought to be at risk for perforation

Viral and bacterial infections:

9. Presence of Hepatitis B surface antigen (HBsAg), (confirmed by Hepatitis B surface antigen test - within 12 months of randomisation) core antigen (HBcAg) or surface antibody (HBsAb), positive Hepatitis C (qualitative enzyme immunoassay) test result

10. Known varicella, herpes zoster, or other severe viral infection within 6 weeks of randomisation

11. The participant has a history of tuberculosis (TB) disease or latent TB infection, in the absence of documented adequate therapy for same.

12. Positive screening test for TB (including T-SPOT.TB TB test), unless respiratory review confirms false positive test results

13. History of uncontrolled bacterial or fungal infection requiring intravenous antibiotics

14. Positive immunoassay for Clostridium difficile toxin and other enteric pathogens

Other exclusion criteria:

15. Cardiology assessment/co-morbidity defined as:

i. QTc >450 msec (480msec for those with Bundle Branch Block) and/or ii. either QTcb or QTcf, machine or manual overread, males or females. The QT correction formula used to determine exclusion and discontinuation should be the same throughout the trial and/or iii. based on single QTc value (average of triplicate readings) of ECG obtained over a brief recording period

16. The participant has congenital or acquired immunodeficiency, or a history of chronic or recurrent opportunistic infections

17. The participant has current evidence of, or has been treated for a malignancy within the past five years (other than localised basal cell, squamous cell skin cancer, cervical dysplasia, or cancer in situ that has been resected)

18. Use of any investigational drug within 30 days prior to screening, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)

19. Participant has received live, attenuated or recombinant vaccine(s) within 2 months of randomisation or will require vaccination within 3 months of trial drug infusion

20. Any patients that are receiving medication(s) detailed in Section 7.11.2 of the trial protocol, will not be eligible for randomisation into the trial